



MASSACHUSETTS  
GENERAL HOSPITAL

CANCER CENTER



## Program

*The Henri and Belinda Termeer Center for Targeted Therapies  
Presents a Roundtable Panel Discussion on*

# Who Will Pay for Tumor Genotyping and Other Advanced Cancer Diagnostics?

5:30 pm

### Welcome and Introductions

Daniel A. Haber, MD, PhD

*Director, Mass General Cancer Center*

Henri A. Termeer

*Former Chairman, President and CEO, Genzyme Corporation*

### Panel Discussion

*Who Will Pay for Tumor Genotyping and Other Advanced Cancer Diagnostics?*

### Moderator

Keith Flaherty, MD

*Director, Henri and Belinda Termeer Center for Targeted Therapies, Mass General Cancer Center*

### Panelists

Marc Grodman, MD

*Chairman, Chief Executive Officer and President, Bio-Reference Laboratories, Inc.*

John Iafrate, MD, PhD

*Director of Molecular Pathology, Massachusetts General Hospital*

Elizabeth Mansfield, PhD

*Director, Personalized Medicine, OIR/CDRH, US Food and Drug Administration*

Ellen Sigal, PhD

*Chairperson and Founder, Friends of Cancer Research*

6:25 pm

### Panel Discussion with Audience

7:15 pm

### Cocktail Reception

# Hosts



## Daniel A. Haber, MD, PhD

Dr. Haber is Director of the Mass General Cancer Center and the Isselbacher/Schwartz Professor of Oncology at Harvard Medical School. His laboratory focuses on cancer genetics and is broadly known for discoveries that have improved the treatment of cancers such as non-small cell lung cancer, breast cancer and Wilms tumor, as well as for innovation in cancer diagnostics.



## Henri A. Termeer

Mr. Termeer served as Chairman, President and Chief Executive Officer of Genzyme Corporation for nearly three decades. Under his leadership, Genzyme grew from a modest entrepreneurial venture into one of the world's leading biotechnology companies. Mr. Termeer resigned from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi. He is a member of the board at both Mass General Hospital and Partners HealthCare.

# Panelists



## Keith T. Flaherty, MD • moderator

Dr. Flaherty is Director of the Henri and Belinda Termeer Center for Targeted Therapies at the Mass General Cancer Center and Associate Professor of Medicine at Harvard Medical School. Dr. Flaherty's research and clinical focus is therapies for melanoma, with a particular expertise in targeted therapies.



## Elizabeth Mansfield, PhD

Dr. Mansfield is the Director of the Personalized Medicine Staff in the Office of In Vitro Diagnostic Devices and Radiological Health (OIR) in the Center for Devices, FDA, where she is developing a program to address companion and novel diagnostic devices. Dr. Mansfield formerly served as the Director of Regulatory Affairs at Affymetrix, Inc., 2004-2006.



## Marc D. Grodman, MD

Dr. Grodman founded BioReference Laboratories, Inc. in 1981 and has been Chairman, President and CEO since its inception. With over 4500 employees and revenues of over \$700 million in FY2013, BioReference has emerged as a major national laboratory in certain specialized areas of clinical medicine, as well as one of the largest full service clinical laboratories in selected regions including the NYC super regional area, the Mid-Atlantic region and Florida.



## Ellen V. Sigal, PhD

Dr. Sigal is Chair and Founder of Friends of Cancer Research (Friends), a think tank and advocacy organization that develops partnerships and advocates for policies that will get treatments and therapies to patients in the safest and quickest way possible. Dr. Sigal holds leadership positions with a broad range of advocacy, public policy and health organizations including: Vice Chair of the board of the Reagan-Udall Foundation for the FDA; Chair of the Public/Private Partnerships Committee of the board of Foundation for the National Institutes of Health; and Governor of the Patient Centered Outcomes Research Institute board.



## Anthony John Iafate, MD, PhD

Dr. Iafate is a board-certified pathologist and Director of Molecular Pathology at Mass General. He oversees a translational research laboratory that has developed high-throughput technologies for rapid and efficient genetic analysis of tumor samples from cancer patients. These technologies have revolutionized cancer diagnostics at Mass General and been adopted by other cancer centers both nationally and internationally.

